Gould Capital LLC Increases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Gould Capital LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 22.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,128 shares of the biopharmaceutical company’s stock after purchasing an additional 2,927 shares during the quarter. Gould Capital LLC’s holdings in Gilead Sciences were worth $1,352,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in GILD. State Street Corp raised its stake in shares of Gilead Sciences by 1.4% during the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after acquiring an additional 841,776 shares during the last quarter. Wellington Management Group LLP increased its holdings in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after purchasing an additional 11,665,593 shares during the period. FMR LLC increased its holdings in Gilead Sciences by 79.4% during the 3rd quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the period. Geode Capital Management LLC raised its position in Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after purchasing an additional 574,421 shares during the last quarter. Finally, Legal & General Group Plc lifted its holdings in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after buying an additional 93,068 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 1.7 %

Shares of GILD stock opened at $90.59 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The stock has a market capitalization of $112.90 billion, a P/E ratio of 1,006.56, a P/E/G ratio of 2.86 and a beta of 0.18. The firm’s 50 day moving average is $89.33 and its 200 day moving average is $78.89.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the business posted $2.29 EPS. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. Research analysts expect that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Royal Bank of Canada upped their target price on Gilead Sciences from $81.00 to $84.00 and gave the company a “sector perform” rating in a report on Monday, November 18th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. The Goldman Sachs Group raised their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Bank of America restated a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a research note on Tuesday. Twelve analysts have rated the stock with a hold rating, twelve have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $96.43.

Insider Activity at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 476,591 shares of company stock worth $43,747,615. 0.29% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.